Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $547,927.00 |
|---|---|
| Enterprise Value | $-4,743,229.00 |
| Earnings per Share | $-25.99 |
| Beta | 0.58 |
| Outstanding Shares | 531,968 |
| P/E Ratio | -0.03 |
|---|---|
| PEG | -0.02 |
| Price to Sales | - |
| Price to Book Ratio | 0.13 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.02 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -8.17 |
| Debt to Equity | 0.69 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.81%▲ 0.51% |
|---|---|
| Total Invested | $31,039▲ 195.36% |
| Investors Holding | 40% |
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelera...